All frozen tumor specimens were obtained from Shengjing Hospital of China Medical University

The cell suspension was ana lyzed on a flow cytometer within 48 hours and ModFit LT was used to fit supplier JNJ-7706621 the data. Statistical analysis Students t tests was performed to analyze data from cells treated with control DMSO or 17 AAG AUY922, as well as cells treated with control scrambled shRNA DMSO or combination of gefitinib, PHA, and AXL shRNA1 AXL shRNA2. Statistically significant differ ences were defined as P 0. 05 and P 0. 01.<br><br> Results Expression and activation of multiple RTKs in ovarian cancer cells By phospho RTK assays, the expression and activation of EGFR, ERBB2, ERBB4 and MET were activated 価格 LDN193189 in SKOV3 cells, and EGFR, MET and AXL in OVCA429 cells, and EGFR in ES2 cells under serum starved medium condition, Activation and or expression of multiple RTK EGFR, ERBB2, ERBB4, MET, and AXL in ovarian cancer cell lines were further validated by immunoblotting with phospho specific antibodies; As shown in Figure 2A, EGFR, ERBB2, ERBB4, and MET in SKOV3, EGFR, MET, and AXL in OVCA429, and EGFR in ES2 were strongly phosphorylated, EGFR, MET, and AXL activation in the ovarian cancer lines was compar able to that in MESO924 cells, which are known to feature strong activation of these RTK, By contrast, activation of EGFR, ERBB2, MET, and AXL was weak to undetectable in Hela cells.<br><br> Co activation and co expression of multiple RTKs were further con firmed in these cells by immunoprecipitation with RTK specific antibodies and immunoblotted with phosphotyr osine antibody, Immunoblotting showed buy LY2228820 strong and moderate p53 expression in ES2 and OVCA429, respectively, whereas p53 was undetectable in SKOV3, We further evaluated the simultaneous expression activation of multiple RTKs by immunoblotting and immunoprecipitation in 15 primary ovarian tumors including 3 non epithelial ovarian tumor, and 12 epithelial ovarian tumors, Receptor EGFR, ERBB2, MET, and AXL were strongly co activated in most primary ovarian tumors, We next compared the inhibitionary effect of tumor cell proliferation between HSP90 inhibitor 17 AAG and various individual kinase inhibitors. EGFR, MET, and AXL signaling pathways in OVCA429 cells were blocked individually by EGFR inhibitor gefitinib, MET inhibitor PHA665752, or shRNA specific to AXL; various combi nation of kinase inhibitors were also performed, As shown in Figure 3A, the most striking reduction in cell viability was seen in cells treated with 17 AAG or com bination of all 3 kinase inhibitors with 75% cell decrease observed.<br><br> EGFR and MET inhibitors alone or together had mild or little effects on cell viability. AXL inhibition by lentiviral shRNA1 and shRNA2 resulted in 50% and 25% inhibition of cell viability in OVCA429, respectively, whereas combination of EGFR MET and AXL inhibition resulted in 65% reduction in viability, The AXL shRNA mediated knockdown resulted in 95% and 60% decrease of AXL protein expres sionin OVCA429, Inactivation of multi RTKs and downstream intermediates by HSP90 inhibition The observation that individual RTK inhibitors have little effect on cell viability, suggested that activation of any one RTK is insufficient to sustain ovar ian cancer growth and or survival.